
Galecto Inc (DMRA) Stock Forecast & Price Target
Galecto Inc (DMRA) Analyst Ratings
Bulls say
Damora Therapeutics is a relatively new biotechnology company with a strong focus on addressing a crucial medical need for patients with hematologic disorders, specifically those with mutant calreticulin-driven myeloproliferative neoplasms. With a diverse pipeline and goal of bringing forward convenient and effective therapies for these conditions, Damora has the potential for significant growth and success in the biotech industry. The involvement of industry experts in their treatments further adds to the credibility and potential success of the company.
Bears say
Damora Therapeutics is targeting a specific subset of patients with hematologic disorders, and while their therapies show potential, there is a risk that their competitors, such as INCA033989, may capture the majority of the market with a head start and established efficacy data. Furthermore, Damora's valuation may seem low given their cash reserves and their expected runway into 2029, but this could be due to uncertainties around their future success and the potential for competitors to outperform their therapies. Overall, there is a significant level of risk associated with investing in Damora Therapeutics at this stage, with a negative outlook for their stock.
This aggregate rating is based on analysts' research of Galecto Inc and is not a guaranteed prediction by Public.com or investment advice.
Galecto Inc (DMRA) Analyst Forecast & Price Prediction
Start investing in Galecto Inc (DMRA)
Order type
Buy in
Order amount
Est. shares
0 shares